[e-drug] GARDP on WHO antibiotic pipeline report

e-drug
1

E-DRUG: GARDP on WHO antibiotic pipeline report
----------------------------------------------------------------

The world is running out of antibiotics, WHO report confirms

A report - 'Antibacterial agents in clinical development' an analysis of
the antibacterial clinical development pipeline, including Mycobacterium
tuberculosis - launched today by the World Health Organization (WHO) shows
a serious lack of new antibiotics under development to combat the growing
threat of antimicrobial resistance.

This report provides firm evidence which confirms that the clinical
pipeline for new antibiotics is extremely weak. This is a major wake-up
call for greater investments into research and development for new
antibiotics. Support also needs to be targeted towards early-stage
research, so that we can start to identify new candidate drugs for
development. It is also critical that the biggest and most urgent public
health needs receive the greatest attention, first and foremost.

The Global Antibiotic Research and Development Partnership (GARDP) was set
up by the World Health Organization (WHO) and the Drugs for Neglected
Diseases initiative (DNDi) to develop new or improved antibiotics to
develop new treatments for key WHO pathogens and important public health
threats such as neonatal sepsis and sexually transmitted infections.

In July of this year, GARDP announced a partnership with Entasis Therapeutics to develop a new treatment to address the rapidly-growing threat of
drug-resistant gonorrhoea.

Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhoea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. The announcement comes as the World Health Organization (WHO) releases alarming new data today showing that of 77 countries surveyed across the world, more than 60% report resistance to the last-resort treatment for gonorrhoea.

Further information here:
<https://www.gardp.org/2017/news-resources/press-releases/entasis-therapeutics-and-gardp-to-develop-new-treatment-for-drug-resistant-gonorrhea/&gt;

Dr Manica Balasegaram, GARDP Director

Rachel M. Cohen
Regional Executive Director
Drugs for Neglected Diseases initiative (DNDi), North America
40 Wall Street, 24th Floor, New York, NY 10005
Web: www.dndi.org
Email: rcohen@dndi.org

2

E-DRUG: GARDP on WHO antibiotic pipeline report (2)
-------------------------------------------------------------------

Dear Balasegaram,
Thank you for highlighting and giving wake up call on Dry antibiotic pipeline.
Most important steps we can take is the judicious use of available antibiotic and monitor the Quality of Antibiotics along with Supply chain integrity.

Most of LMIC lacks a credible QA&QC system and use of Low quality antibiotic. Specially, in capacity and credibility of NQCL, which plays important role in Quality monitoring in pre and Post marketing, most of Labs are not performing complete compendia testing which leads to substandard Antibiotics in Market.

Most sources of APIs are unqualified.

Although in few Counties USP PQM with the financial support of USAID Mission is working on this issue and supporting Labs and Industry to improve their processes.But there is still need to strengthen these efforts on war footing.

Dr Syed Khalid Saeed Bukhari,
Senior County Consultant USP,
Promoting the Quality of Medicines (PQM) Program
U.S. Pharmacopeial Convention
Rockville, MD 20852-1790 - USA
Dr Khalid Saeed Bukhari <skhs77@gmail.com>